Optimizing lipid lowering in patients at risk

Clinical Cardiology
Luther T Clark

Abstract

The efficacy of statins in lowering low-density lipoprotein cholesterol (LDL-C) and reducing coronary heart disease risk is well established; however, recent evidence suggests that more aggressive lipid management, even beyond achievement of currently recommended LDL-C goals, may provide additional clinical benefits. A novel approach to the aggressive lowering of LDL-C is the combination of statins with agents that affect different aspects of cholesterol metabolism. Because absorption of cholesterol is an important contributor to cholesterol balance, the simultaneous inhibition of cholesterol absorption and cholesterol synthesis is an attractive approach to achieving greater LDL-C reductions. In clinical trials, the combination of the cholesterol absorption inhibitor ezetimibe with a statin resulted in greater improvements in lipids than statin monotherapy and allowed a greater percentage of patients to achieve treatment goals. In addition, this combination may offer benefits through reduction of phytosterols, chylomicron remnants, and C-reactive protein. Several ongoing trials are evaluating whether the benefit of simultaneously blocking cholesterol synthesis and intestinal cholesterol absorption translates into better clinica...Continue Reading

References

Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jul 11, 2001·Pharmacotherapy·R J StrakaA C Smith
Oct 9, 2002·Circulation·Thomas SudhopKlaus von Bergmann
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Dec 19, 2002·Metabolism: Clinical and Experimental·Thomas SudhopKlaus von Bergmann
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group
Dec 17, 2003·The American Journal of Cardiology·Philip T SagerUNKNOWN Ezetimibe Study Group
Feb 11, 2004·Circulation·G SalenUNKNOWN Multicenter Sitosterolemia Study Group
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.